This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.
Pancreatic cancer arises when cells in the pancreas, a glandular
organ behind the stomach, grow and divide out of control and form a
tumor. In 2020, it is estimated that pancreatic cancer will be
responsible for 45,750 deaths and 56,770 new cases. Pancreatic
cancer accounts for about 3% of all cancers in the US and about 7%
of all cancer deaths. Despite treatment advances, pancreatic cancer
is associated with a relatively poor outcome for most patients.
Pancreatic cancer remains among the most challenging malignancies to
treat, but ongoing clinical research is continually emerging with
the potential to improve outcomes and patient care. Fortunately for
patients with pancreatic cancer, several new treatment options,
including PARP inhibitors, have become available in recent years or
have recently undergone successful late stage clinical trials. They
have shown the ability to improve safety and efficacy outcomes,
especially in patients with a BRCA mutation. With these recent
advances in the management of pancreatic cancer, it is critical to
provide medical directors, oncologists, practicing physicians and
others on the interprofessional management team with updated
clinical trial data and strategies on the changing treatment
paradigm, with the ultimate goal of improving patient outcomes.
With the advancement and complexity of different treatment options,
clinicians are being challenged to quickly diagnose pancreatic
cancer and its corresponding stage, and provide the best
evidenced-based treatment that is available for patients. Clinicians
are increasingly able to select more potent - and soon, more
targeted - options for disease management. In the wake of these
advances, other innovative therapies are being rapidly developed,
from stroma- and BRCA-targeting agents, to immunotherapy and tumor
treating fields. New classes of targeted agents are in development
for pancreatic cancer for the first time, including PARP inhibitors.
Recent studies have shown that PARP inhibitors have significantly
delayed the progression of metastatic pancreatic cancer in patients
with BRCA gene mutations. The complexities of today's more
personalized care pose multiple challenges to effective clinical and
economic management of pancreatic cancer. It is for this reason that
medical directors, oncologists, nurses and other healthcare
professionals are provided with a detailed overview of current and
emerging strategies for pancreatic cancer, with a focus on
patient-centric therapy. A review of the most recent clinical trial
data for molecularly targeted therapies will be provided, as will a
discussion of new and emerging drug classes.
Upon completion of this
activity, participants will be able to:
Describe the mechanistic rationale
for targeting DDR in the treatment of patients with pancreatic
Analyze recent clinical data on the
safety and efficacy of new and emerging therapies, including
PARP inhibitors, for patients with pancreatic cancer
Explore the role of PARP inhibitors
in the evolving pancreatic cancer treatment paradigm
Identify patients with pancreatic
cancer that are most likely to benefit from treatments with PARP
Outline evidence pertaining to
biomarker studies that may guide the use of PARP inhibition in
Assess the managed care
considerations of PARP inhibitors by exploring where these
agents fit in the current pancreatic management paradigm
||Tanios Bekaii-Saab, MD,
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer, Mayo Clinic
Vice-Chair and Section Lead, Division of Medical
Senior Associate Consultant, Mayo Clinic AZ
serves as a consultant for Array Biopharma, Bayer,
Boehringer Ingelheim, Celularity, Daiichi Sankyo, Eisai,
Exact Science, Genentech, Incyte, Ipsen, Janssen, Merck,
Natera, Pfizer, Seattle Genetics, Sobi, and TreosBio. He
serves on an advisory board for Imugene, Immuneering,
and Sun Biopharma. He has received grants/research
support from Agios, Arys, Boston Biomedical, Bayer,
Amgen, Merck, Celgene, Lilly, Ipsen, Clovis, Seattle
Genetics, Array Biopharma, Genentech, Novartis, Mirati,
Merus, Abgenomics, Incyte, Pfizer, and BMS. His
presentation has been peer reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue